Alcon Vision LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$98Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
55,491clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Total30 $4.7M associated (2023-2025)
- Clareon $4.7M associated (2023-2025)
- Dailies Total1 $3.7M associated (2023-2025)
- Precision 1 $3.6M associated (2023-2025)
- Hydrus Microstent $2.8M associated (2023-2025)
- Precision7 $2.3M associated (2023-2025)
- Tryptyr $2.3M associated (2023-2025)
- Rocklatan $2.1M associated (2023-2025)
- Rhopressa $1.5M associated (2023-2025)
- Acrysof Iq Panoptix Uv Iol $1.4M associated (2023-2025)
- Constellation $1.2M associated (2023-2025)
- Acrysof Iq Vivity $975K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Guy Kezirian | Paradise Valley, AZ | $11,353,576.41 | |
| Edwin Ryan | Minneapolis, MN | Ophthalmology | $9,300,497.21 |
| Michael Berlin | West Hollywood, CA | Ophthalmology | $5,659,939.59 |
| Steve Charles | Germantown, TN | Retina Specialist | $4,407,277.67 |
| Mark Lobanoff | St Louis Park, MN | Ophthalmology | $1,971,443.06 |
| Kenneth Miller | Danbury, CT | Rheumatology | $872,840.32 |
| Preeya Gupta | Raleigh, NC | Ophthalmology | $727,464.98 |
| John Berdahl | Sioux Falls, SD | Ophthalmology | $677,205.16 |
| Khosrow Mehrany | Modesto, CA | $566,898.02 | |
| Claudio Lagunas | Houston, TX | Optometrist | $563,531.06 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.